Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Construction in Progress (2016 - 2025)

Historic Construction in Progress for BeOne Medicines (BEIGF) over the last 9 years, with Q3 2025 value amounting to $129.1 million.

  • BeOne Medicines' Construction in Progress fell 7936.24% to $129.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.1 million, marking a year-over-year decrease of 7936.24%. This contributed to the annual value of $654.0 million for FY2024, which is 1169.26% down from last year.
  • Per BeOne Medicines' latest filing, its Construction in Progress stood at $129.1 million for Q3 2025, which was down 7936.24% from $353.7 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Construction in Progress ranged from a high of $863.4 million in Q2 2024 and a low of $70.8 million during Q1 2021
  • Moreover, its 5-year median value for Construction in Progress was $365.3 million (2023), whereas its average is $409.3 million.
  • Its Construction in Progress has fluctuated over the past 5 years, first skyrocketed by 18401.79% in 2023, then tumbled by 7936.24% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Construction in Progress stood at $186.8 million in 2021, then soared by 57.15% to $293.6 million in 2022, then surged by 152.23% to $740.6 million in 2023, then decreased by 11.69% to $654.0 million in 2024, then plummeted by 80.26% to $129.1 million in 2025.
  • Its last three reported values are $129.1 million in Q3 2025, $353.7 million for Q2 2025, and $590.0 million during Q1 2025.